Targeting Mammalian Target of Rapamycin: Prospects for the Treatment of Inflammatory Bowel Diseases

Author(s): Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz, Negar Ghanaatian, Parichehr Kohansal, Mohammad Hosein Farzaei, Khashayar Afshari, Amirhossein Sahebkar*, Amir Hossein Abdolghaffari*

Journal Name: Current Medicinal Chemistry

Volume 28 , Issue 8 , 2021

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Inflammatory bowel disease (IBD) is a general term for a group of chronic and progressive disorders. Several cellular and biomolecular pathways are implicated in the pathogenesis of IBD, yet the etiology is unclear. Activation of the mammalian target of rapamycin (mTOR) pathway in the intestinal epithelial cells was also shown to induce inflammation. This review focuses on the inhibition of the mTOR signaling pathway and its potential application in treating IBD. We also provide an overview of plant-derived compounds that are beneficial for the IBD management through modulation of the mTOR pathway. Data were extracted from clinical, in vitro and in vivo studies published in English between 1995 and May 2019, which were collected from PubMed, Google Scholar, Scopus and Cochrane library databases. Results of various studies implied that inhibition of the mTOR signaling pathway downregulates the inflammatory processes and cytokines involved in IBD. In this context, a number of natural products might reverse the pathological features of the disease. Furthermore, mTOR provides a novel drug target for IBD. Comprehensive clinical studies are required to confirm the efficacy of mTOR inhibitors in treating IBD.

Keywords: Gastroenterology, inflammatory bowel disease, ulcerative colitis, crohn’s disease, mammalian target of rapamycin, natural products.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 03 May, 2020
Page: [1605 - 1624]
Pages: 20
DOI: 10.2174/0929867327666200504081503
Price: $65

Article Metrics

PDF: 158